This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.
This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.

If you are a UK healthcare professional, visit MSD Connect for professional information.

Information for UK members of the public

This website contains information about medicines supplied by MSD in the UK. These medicines are only available on prescription and this website is not intended to replace the advice of a healthcare professional.

You can use this website to find:

  • General information about MSD medicines and vaccines
  • Information for patients who have been prescribed MSD medicines and vaccines
  • Information about diseases and treatments

You should consult your doctor or another suitably trained healthcare professional when considering what type of treatment is most appropriate for you or if you have any questions about medicines prescribed to you.

Want to know more about MSD in the UK? Please visit our corporate page:

Find out about MSD

Our products are listed alphabetically in groups. You can find out more about our products by using the tabs below to display each group.

You can find out more about some of the diseases and treatment areas we provide medicines for in the list below.

Adempas® (riociguat) 0.5 mg Film-Coated Tablets
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report

Adempas® (riociguat) 1.0 mg Film-Coated Tablets
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report

Adempas® (riociguat) 1.5 mg Film-Coated Tablets
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report

Adempas® (riociguat) 2.0 mg Film-Coated Tablets
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report

Adempas® (riociguat) 2.5 mg Film-Coated Tablets
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report

Arcoxia® (etoricoxib) 30 mg Film-Coated Tablets
Patient Information Leaflet | Summary of Product Characteristics

Arcoxia® (etoricoxib) 60 mg Film-Coated Tablets
Patient Information Leaflet | Summary of Product Characteristics

Arcoxia® (etoricoxib) 90 mg Film-Coated Tablets
Patient Information Leaflet | Summary of Product Characteristics

Arcoxia® (etoricoxib) 120 mg Film-Coated Tablets
Patient Information Leaflet | Summary of Product Characteristics

Asmanex® (mometasone furoate) 200 mcg Twisthaler Inhalation Powder
Patient Information Leaflet | Summary of Product Characteristics

Asmanex® (mometasone furoate) 400 mcg Twisthaler Inhalation Powder
Patient Information Leaflet | Summary of Product Characteristics

Bridion® (sugammadex sodium) 100 mg/ml Solution for Injection
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report

Cancidas® (caspofungin acetate) 50 mg Powder for Concentrate for Solution for Infusion
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report

Cancidas® (caspofungin acetate) 70 mg Powder for Concentrate for Solution for Infusion
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report

Cerazette® (desogestrel) 75 mcg Film-Coated Tablets
Patient Information Leaflet | Summary of Product Characteristics

Cozaar® Comp (losartan potassium/hydrochlorothiazide) 50/12.5 mg Film-Coated Tablets
Patient Information Leaflet | Summary of Product Characteristics

Cozaar® Comp (losartan potassium/hydrochlorothiazide) 100/12.5 mg Film-Coated Tablets
Patient Information Leaflet | Summary of Product Characteristics

Cozaar® Comp (losartan potassium/hydrochlorothiazide) 100/25 mg Film-Coated Tablets
Patient Information Leaflet | Summary of Product Characteristics

Cozaar® (losartan potassium) 12.5 mg Film-Coated Tablets
Patient Information Leaflet | Summary of Product Characteristics

Cozaar® (losartan potassium) 25 mg Film-Coated Tablets
Patient Information Leaflet | Summary of Product Characteristics

Cozaar® (losartan potassium) 50 mg Film-Coated Tablets
Patient Information Leaflet | Summary of Product Characteristics

Cozaar® (losartan potassium) 100 mg Film-Coated Tablets
Patient Information Leaflet | Summary of Product Characteristics

Cubicin® (daptomycin) 350 mg Powder for Solution for Injection or Infusion
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report

Cubicin® (daptomycin) 500 mg Powder for Solution for Injection or Infusion
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report

Delstrigo® (doravirine/lamivudine/tenofovir disoproxil fumarate) 100 mg/300 mg/245 mg Film-Coated Tablets
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report

This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See https://yellowcard.mhra.gov.uk for how to report side effects or search for MHRA Yellow Card in the Google Play or Apple App Store.

Diprosalic® (salicylic acid/betamethasone dipropionate) Ointment
Patient Information Leaflet | Summary of Product Characteristics

Diprosalic® (salicylic acid/betamethasone dipropionate) Scalp Application
Patient Information Leaflet | Summary of Product Characteristics

Diprosone® (betamethasone dipropionate) Cream
Patient Information Leaflet | Summary of Product Characteristics

Diprosone® (betamethasone dipropionate) Lotion
Patient Information Leaflet | Summary of Product Characteristics

Diprosone® (betamethasone dipropionate) Ointment
Patient Information Leaflet | Summary of Product Characteristics

Elocon® (mometasone furoate) Cream
Patient Information Leaflet | Summary of Product Characteristics

Elocon® (mometasone furoate) Ointment
Patient Information Leaflet | Summary of Product Characteristics

Elocon® (mometasone furoate) Scalp Lotion
Patient Information Leaflet | Summary of Product Characteristics

Emend® (aprepitant) 80 mg Hard Capsules
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report

Emend® (aprepitant) 125 mg Hard Capsules
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report

Emend® (aprepitant) 125 mg Powder for Oral Suspension
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report

Esmeron® (rocuronium bromide) 10 mg/ml Solution for Injection
Patient Information Leaflet | Summary of Product Characteristics

Ezetrol® (ezetimibe) 10 mg Tablets
Patient Information Leaflet | Summary of Product Characteristics

Fosamax® (alendronate sodium trihydrate) 70 mg Once Weekly Tablets
Patient Information Leaflet | Summary of Product Characteristics

Fosavance® (alendronate sodium trihydrate/colecalciferol [vitamin D3]) Tablet
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report

Gardasil® (Human Papillomavirus Vaccine [Type 6,11,16,18]) (Recombinant, adsorbed) Suspension for Injection in a Prefilled Syringe or Vial
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report

Gardasil®9 (Human Papillomavirus 9-valent vaccine) (Recombinant, adsorbed) Suspension for Injection in a Prefilled Syringe or Vial
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report

HBVaxPro® (hepatitis B vaccine rDNA) 5 mcg Suspension for Injection in Pre-filled Syringe
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report

HBVaxPro® (hepatitis B vaccine rDNA) 10 mcg Suspension for Injection in Pre-filled Syringe
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report

HBVaxPro® (hepatitis B vaccine rDNA) 40 mcg Suspension for Injection in Pre-filled Syringe
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report

Inegy® (ezetimibe/simvastatin) 10 mg/20 mg Tablets
Patient Information Leaflet | Summary of Product Characteristics

Inegy® (ezetimibe/simvastatin) 10 mg/40 mg Tablets
Patient Information Leaflet | Summary of Product Characteristics

Inegy® (ezetimibe/simvastatin) 10 mg/80 mg Tablets
Patient Information Leaflet | Summary of Product Characteristics

Innovace® (enalapril maleate) 2.5 mg Tablets
Patient Information Leaflet | Summary of Product Characteristics

Innovace® (enalapril maleate) 5 mg Tablets
Patient Information Leaflet | Summary of Product Characteristics

Innovace® (enalapril maleate) 10 mg Tablets
Patient Information Leaflet | Summary of Product Characteristics

Innovace® (enalapril maleate) 20 mg Tablets
Patient Information Leaflet | Summary of Product Characteristics

Innozide® (enalapril maleate/hydrochlorothiazide) 20/12.5 mg Tablets
Patient Information Leaflet | Summary of Product Characteristics

Invanz® (ertapenem sodium) 1 g Powder for Concentrate for Solution for Infusion
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report

Isentress® (raltegravir potassium) 25 mg Chewable Tablets
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report

Isentress® (raltegravir potassium) 100 mg Chewable Tablets
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report

Isentress® (raltegravir potassium) 100 mg Granules for Oral Suspension
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report

Isentress® (raltegravir potassium) 400 mg Film-Coated Tablets
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report

Isentress® (raltegravir potassium) 600 mg Film-Coated Tablets
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report

IVEMEND® (fosaprepitant dimeglumine) 150 mg Powder for Solution for Infusion
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report

Janumet® (sitagliptin phosphate monohydrate/metformin hydrochloride) 50 mg/1,000 mg Film-Coated Tablets
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report

Januvia® (sitagliptin phosphate monohydrate) 25 mg Film-Coated Tablets
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report

Januvia® (sitagliptin phosphate monohydrate) 50 mg Film-Coated Tablets
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report

Januvia® (sitagliptin phosphate monohydrate) 100 mg Film-Coated Tablets
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report

Keytruda® (pembrolizumab) 25 mg/ml Concentrate for Solution for Infusion
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report
NICE | ClinicalTrials.gov

Keytruda® (pembrolizumab) 50 mg Powder for Concentrate for Solution for Infusion
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report
NICE | ClinicalTrials.gov
Further information for patients

Lenvima® (lenvatinib mesilate) 4 mg Hard Capsules
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report

Lenvima® (lenvatinib mesilate) 10 mg Hard Capsules
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report

Marketing Authorisation Holder: Eisai GmbH, Lyoner Straße 36, 60528 Frankfurt am Main, Germany.

This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See https://yellowcard.mhra.gov.uk for how to report side effects or search for MHRA Yellow Card in the Google Play or Apple App Store.

Livial® (tibolone) 2.5 mg Tablets
Patient Information Leaflet | Summary of Product Characteristics

Lotriderm® (betamethasone dipropionate/clotrimazole) Cream
Patient Information Leaflet | Summary of Product Characteristics

Lynparza(olaparib) 100 mg Film-Coated Tablets
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report

Lynparza(olaparib) 150 mg Film-Coated Tablets
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report

Lynparza(olaparib) 50 mg Hard Capsules
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report

Marketing Authorisation Holder: AstraZeneca AB, SE-151 85 Södertälje, Sweden.

Marvelon® (desogestrel/ethinylestradiol) 150/30 mcg Tablets
Patient Information Leaflet | Summary of Product Characteristics

Maxalt Melt® (rizatriptan benzoate) 10 mg Oral Lyophilisates
Patient Information Leaflet | Summary of Product Characteristics

Maxalt® (rizatriptan benzoate) 5 mg Tablets
Patient Information Leaflet | Summary of Product Characteristics

Maxalt® (rizatriptan benzoate) 10 mg Tablets
Patient Information Leaflet | Summary of Product Characteristics

Mercilon® (desogestrel/ethinylestradiol) 150/20 mcg Tablets
Patient Information Leaflet | Summary of Product Characteristics

MMRVaxPro® (measles, mumps and rubella vaccine [live]) Powder and Solvent for Suspension for Injection in Pre-filled Syringe
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report

Moduretic® (hydrochlorothiazide/amiloride hydrochloride) 50 mg/5 mg Tablets
Patient Information Leaflet | Summary of Product Characteristics

Nasonex® (mometasone furoate monohydrate) 50 mcg/actuation Nasal Spray
Patient Information Leaflet | Summary of Product Characteristics

Neoclarityn® (desloratadine) 5 mg Film-Coated Tablets
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report

Neoclarityn® (desloratadine) 0.5 mg/ml Oral Solution
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report

Nexplanon® (etonogestrel) 68 mg Implant for Subdermal Use
Patient Information Leaflet | Summary of Product Characteristics

Noxafil® (posaconazole) 300 mg Concentrate for Solution for Infusion
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report

Noxafil® (posaconazole) 100 mg Gastro-Resistant Tablets
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report

Noxafil® (posaconazole) 40 mg/ml Oral Suspension
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report

Nuvaring® (etonogestrel/ethinylestradiol) Vaginal Delivery System
Patient Information Leaflet | Summary of Product Characteristics

OncoTICE® (2-8 x 108 CFU Tice bacillus calmette-guérin) Powder for Instillation Fluid for Intravesical Use
Patient Information Leaflet | Summary of Product Characteristics

Ontruzant® (trastuzumab) 150 mg Powder for Concentrate for Solution for Infusion
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report

This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See https://yellowcard.mhra.gov.uk for how to report side effects or search for MHRA Yellow Card in the Google Play or Apple App Store.

Pifeltro® (doravirine) 100 mg Film-Coated Tablets
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report

This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See https://yellowcard.mhra.gov.uk for how to report side effects or search for MHRA Yellow Card in the Google Play or Apple App Store.

Pneumococcal polysaccharide vaccine (pneumococcal vaccine polyvalent) Solution for Injection in a Vial
Patient Information Leaflet | Summary of Product Characteristics

Pneumovax® 23 (pneumococcal vaccine polyvalent) Solution for Injection in Pre-filled Syringe
Patient Information Leaflet | Summary of Product Characteristics

Prevymis® (letermovir) 240 mg Film-Coated Tablets
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report

This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See https://yellowcard.mhra.gov.uk for how to report side effects or search for MHRA Yellow Card in the Google Play or Apple App Store.

Primaxin® IV (imipenem monohydrate/cilastatin sodium) 500 mg/500 mg Powder for Solution for Infusion
Patient Information Leaflet | Summary of Product Characteristics

Propecia® (finasteride) 1 mg Film-Coated Tablets
Patient Information Leaflet | Summary of Product Characteristics
Further information for patients

Proscar® (finasteride) 5 mg Film-Coated Tablets
Patient Information Leaflet | Summary of Product Characteristics

Rebetol® (ribavirin) 200 mg Hard Capsules
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report

Rebetol® (ribavirin) 40 mg/ml Oral Solution
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report

Remicade® (infliximab) 100 mg Powder for Concentrate for Solution for Infusion
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report
Further information for patients

Restandol® Testocaps (testosterone undecanoate) 40 mg Soft Capsules
Patient Information Leaflet | Summary of Product Characteristics

Simponi® (golimumab) 50 mg Solution for Injection in Pre-Filled Pen
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report
Further information for patients

Simponi® (golimumab) 50 mg Solution for Injection in Pre-Filled Syringe
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report
Further information for patients

Simponi® (golimumab) 100 mg Solution for Injection in Pre-Filled Pen
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report
Further information for patients

Half Sinemet CR (carbidopa/levodopa) 25 mg/100 mg Prolonged-Release Tablets
Patient Information Leaflet | Summary of Product Characteristics

Sinemet® (carbidopa/levodopa) 12.5 mg/50 mg Tablets
Patient Information Leaflet | Summary of Product Characteristics

Sinemet® (carbidopa/levodopa) 10 mg/100 mg Tablets
Patient Information Leaflet | Summary of Product Characteristics

Sinemet® (carbidopa/levodopa) 25 mg/250 mg Tablets
Patient Information Leaflet | Summary of Product Characteristics

Sinemet® CR (carbidopa/levodopa) 50 mg/200 mg Prolonged-Release Tablets
Patient Information Leaflet | Summary of Product Characteristics

Sinemet Plus (carbidopa/levodopa) 25 mg/100 mg Tablets
Patient Information Leaflet | Summary of Product Characteristics

Singulair® (montelukast sodium) 10 mg Tablets
Patient Information Leaflet | Summary of Product Characteristics

Singulair® Paediatric (montelukast sodium) 4 mg Chewable Tablets
Patient Information Leaflet | Summary of Product Characteristics

Singulair® Paediatric (montelukast sodium) 5 mg Chewable Tablets
Patient Information Leaflet | Summary of Product Characteristics

Singulair® Paediatric (montelukast sodium) 4 mg Granules
Patient Information Leaflet | Summary of Product Characteristics

Sivextro®(tedizolid phosphate) 200 mg Film-Coated Tablets
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report

Sivextro®(tedizolid phosphate) 200 mg Powder for Concentrate for Solution for Infusion
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report

This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See https://yellowcard.mhra.gov.uk for how to report side effects or search for MHRA Yellow Card in the Google Play or Apple App Store.

Steglatro®(ertugliflozin L-pyroglutamic acid) 5 mg Film-Coated Tablets
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report

Steglatro®(ertugliflozin L-pyroglutamic acid) 15 mg Film-Coated Tablets
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report

This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See https://yellowcard.mhra.gov.uk for how to report side effects or search for MHRA Yellow Card in the Google Play or Apple App Store.

Temodal® (temozolomide) 5 mg/20 mg/100 mg/140 mg/180 mg/250 mg Hard Capsules
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report

VAQTA® Adult (hepatitis A vaccine, inactivated, adsorbed) Suspension for Injection in a Prefilled Syringe or Vial
Patient Information Leaflet | Summary of Product Characteristics

VAQTA® Paediatric (hepatitis A vaccine, inactivated, adsorbed) Suspension for Injection in a Prefilled Syringe or Vial
Patient Information Leaflet | Summary of Product Characteristics

Varivax® (varicella virus vaccine [live]) Powder and Solvent for Suspension for Injection
Patient Information Leaflet | Summary of Product Characteristics

Zepatier®(elbasvir/grazoprevir) 50 mg/100 mg Film-Coated Tablets
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report

This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See https://yellowcard.mhra.gov.uk for how to report side effects or search for MHRA Yellow Card in the Google Play or Apple App Store.

Zerbaxa® (ceftolozane sulfate/tazobactam sodium) 1 g/0.5 g Powder for Concentrate for Solution for Infusion
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report

Zinplava®(bezlotoxumab) 25 mg/ml Concentrate for Solution for Infusion
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report

This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See https://yellowcard.mhra.gov.uk for how to report side effects or search for MHRA Yellow Card in the Google Play or Apple App Store.

Zispin SolTab® (mirtazapine) 15 mg Orodispersible Tablets
Patient Information Leaflet | Summary of Product Characteristics

Zispin SolTab® (mirtazapine) 30 mg Orodispersible Tablets
Patient Information Leaflet | Summary of Product Characteristics

Zispin SolTab® (mirtazapine) 45 mg Orodispersible Tablets
Patient Information Leaflet | Summary of Product Characteristics

Zocor® (simvastatin) 10 mg Film-Coated Tablets
Patient Information Leaflet | Summary of Product Characteristics

Zocor® (simvastatin) 20 mg Film-Coated Tablets
Patient Information Leaflet | Summary of Product Characteristics

Zocor® (simvastatin) 40 mg Film-Coated Tablets
Patient Information Leaflet | Summary of Product Characteristics

Zocor® (simvastatin) 80 mg Film-Coated Tablets
Patient Information Leaflet | Summary of Product Characteristics

Zoely®(estradiol hemihydrate/nomegestrol acetate) 2.5 mg/1.5 mg Film-Coated Tablets
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report

This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See https://yellowcard.mhra.gov.uk for how to report side effects or search for MHRA Yellow Card in the Google Play or Apple App Store.

Zostavax® (shingles [herpes zoster] vaccine [live]) Powder and Solvent for Suspension for Injection
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report

Anaesthesia
Antibiotics
Ankylosing spondylitis
Aspergillosis
Cancer
Crohn's disease
Contraception
Cytomegalovirus (CMV)
Diabetes
Hepatitis C
Human immunodeficiency virus (HIV)
Male pattern hair loss (MPHL)
Non-radiographic axial spondyloarthritis (nr-Axial SpA)
Psoriasis
Psoriatic arthritis
Pulmonary hypertension
Rheumatoid arthritis
Ulcerative colitis
Vaccines